Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-9788
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics ; volume:2 ; number:4 ; day:13 ; month:10 ; year:2015 ; pages:377-385 ; date:12.2015
Drugs - real world outcomes ; 2, Heft 4 (13.10.2015), 377-385, 12.2015
- Creator
-
Pesa, Jacqueline A.
Muser, Erik
Montejano, Leslie B.
Smith, David M.
Meyers, Oren I.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40801-015-0043-4
- URN
-
urn:nbn:de:101:1-2019063018520919806865
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-14T10:48:23+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pesa, Jacqueline A.
- Muser, Erik
- Montejano, Leslie B.
- Smith, David M.
- Meyers, Oren I.
- SpringerLink (Online service)
Other Objects (12)
Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics
Atypical antipsychotics
Diabetes and atypical antipsychotics
Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation
Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics—a European study
Clinical pharmacology of atypical antipsychotics: an update
Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
Atypical antipsychotics in the treatment of schizophrenic patients
Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics
Atypical antipsychotics
Diabetes and atypical antipsychotics
Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation
Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics—a European study
Clinical pharmacology of atypical antipsychotics: an update
Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
Atypical antipsychotics in the treatment of schizophrenic patients
Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics
Atypical antipsychotics
Diabetes and atypical antipsychotics
Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation
Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics—a European study
Clinical pharmacology of atypical antipsychotics: an update
Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics